AI-Powered Drug Could Reduce Aging Markers

A new study published in the journal Nature Biotechnology revealed that rentosertib, an AI-developed drug by Insilico Medicine, achieved early success in reducing biological aging indicators in 12-week trials conducted on a small group of participants.

Key Findings of the Research

A new study published in the journal Nature Biotechnology examined the potential effects of the AI-generated drug rentosertib on aging processes.

The primary goal of the drug, developed by Insilico Medicine, was announced as both treating chronic lung patients and extending lifespan.

Aging Clocks and Measurements

As part of the research, six different AI-developed aging clocks were used to measure biological age.

These clocks aim to reflect overall health by taking blood biomarkers, physiological measurements, and psychological evaluations into account.

12-Week Trial Period

The effects of the drug were observed during a 12-week trial process conducted on 42 participants included in the study.

While a decrease in biological age was observed in participants using the drug, an increase or stabilization in age was recorded for those taking a placebo or receiving no treatment.

Expert Debates and the Future

Although the idea of reducing aging creates excitement, the true utility of aging clocks remains a subject of debate within the scientific world.

The drug still faces a long clinical testing process before it can receive regulatory approval and be used in large-scale treatments.